Rheumatology

CTD-ILD

Questions discussed in this category

Would you initiate antifibrotic therapy in a patient with CTD-ILD experiencing worsening symptoms and declining lung function, despite no clear evidence of fibrosis on CT scans?

CT changes are subsolid and ground glass nodules.

1 Answer available

What is your approach to management of pulmonary fibrosis in patients with a history of microscopic polyangiitis who do not have other active organ involvement?

Patient is with past history of glomerulonephritis in remission after rituximab for the past 2 years. +MPO/P-ANCA

1 Answer available

What dose and duration of steroid therapy do you employ while starting mycophenolate in an outpatient with relatively stable CTD-ILD?

Do you ever start mycophenolate without steroids?

1 Answer available

In light of the RECITAL study, would rituximab be a reasonable choice in a patient with PL-12 antibodies, rapidly progressive pulmonary disease with organizing pneumonia on biopsy?

Given poor pulmonary outcomes in people with anti-PL12 antibodies, would you recommend more aggressive therapy? The patient was diagnosed with onset o...

1 Answer available

Is it safe to combine mycophenolate and adalimumab for management of pulmonary sarcoidosis in a patient that could not tolerate methotrexate?

3 Answers available

How would you approach treatment of active inflammatory arthritis in a patient with MCTD (+RNP/+Chromatin) and stable ILD who has failed MMF, azathioprine and methotrexate?

Would you consider belimumab over a TNF inhibitor for inflammatory arthritis? Which agent would be more beneficial for the lung disease?

2 Answers available

What is your approach to steroid sparing therapy in patients with suspected CTD-ILD?

2 Answers available

Papers discussed in this category

The Lancet. Respiratory medicine, 2016-09

Mycophenolate mofetil versus oral cyclophosphamide in scleroderma-related interstitial lung disease (SLS II): a randomised controlled, double-blind, parallel group trial.

Respirology, 2013 Nov 29

Rituximab in severe, treatment-refractory interstitial lung disease.

Respir Res, 2022 Jun 21

Effect size of rituximab on pulmonary function in the treatment of connective-tissue disease-related interstitial lung disease: a systematic review and meta-analysis.

Arthritis & rheumatology (Hoboken, N.J.), 2015-05

Clinical utility of random anti-tumor necrosis factor drug-level testing and measurement of antidrug antibodies on the long-term treatment response in rheumatoid arthritis.

International journal of rheumatic diseases, 2014-02

Neurosarcoidosis mimicking multiple sclerosis successfully treated with methotrexate and adalimumab.

Sarcoidosis, vasculitis, and diffuse lung diseases : official journal of WASOG, 2014-04-18

Efficacy Results of a 52-week Trial of Adalimumab in the Treatment of Refractory Sarcoidosis.

Clinical nuclear medicine, 2016-05

FDG PET/CT Evidence of Effective Treatment of Cardiac Sarcoidosis With Adalimumab.

J Investig Med High Impact Case Rep, 2021 Jan-Dec

Pituitary Sarcoidosis in a Pediatric Patient Successfully Treated With Adalimumab and Methotrexate.

Clinical therapeutics, 2018 Feb

Methotrexate Dose in Patients With Early Rheumatoid Arthritis Impacts Methotrexate Polyglutamate Pharmacokinetics, Adalimumab Pharmacokinetics, and Efficacy: Pharmacokinetic and Exposure-response Analysis of the CONCERTO Trial.

Seminars in arthritis and rheumatism, 2018 Jan 06

Abatacept in patients with rheumatoid arthritis and interstitial lung disease: A national multicenter study of 63 patients.

Lancet Respir Med, 2023 Jan

Rituximab versus intravenous cyclophosphamide in patients with connective tissue disease-associated interstitial lung disease in the UK (RECITAL): a double-blind, double-dummy, randomised, controlled, phase 2b trial.

Current opinion in pulmonary medicine, 2023 Jun 30

Interstitial lung disease in patients with anti-neutrophil cytoplasm antibody-associated vasculitis: an update on pathogenesis and treatment.

Rheumatology (Oxford, England), 2023 Feb 01

Interstitial lung disease in ANCA-associated vasculitis: associated factors, radiographic features and mortality.

N. Engl. J. Med., 2019 May 20

Nintedanib for Systemic Sclerosis-Associated Interstitial Lung Disease.

N Engl J Med, 2019 Sep 29

Nintedanib in Progressive Fibrosing Interstitial Lung Diseases.

Rheumatology

CTD-ILD

Questions discussed in this category

Papers discussed in this category

Related Topics in Rheumatology